Authors: | Kaptain, S.; Tan, L. K.; Chen, B. |
Article Title: | Her-2/neu and breast cancer |
Abstract: | Breast cancer is the most common malignancy in women in the United States in the year 2000. The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important prognostic and predictive factor in breast cancer. Overexpression/amplification of the Her-2/neu has been associated with a worse outcome in patients with breast cancer. Herceptin, a "humanized" murine monoclonal antibody directed against the extracellular domain of the Her-2/neu protein, is being used to treat breast cancer that overexpresses Her-2/neu. The status of Her-2/neu in the tumor has become a critical factor in the management strategy of a breast cancer patient. The objective of this article is to provide a comprehensive review of all aspects of Her-2/neu in breast cancer, including biology, prognostic and predictive value, targeted Herceptin therapy, and the laboratory testing of Her-2/neu. |
Keywords: | immunohistochemistry; clinical trial; review; cisplatin; doxorubicin; antineoplastic agents; paclitaxel; antineoplastic agent; protein domain; adenocarcinoma; gene overexpression; proto oncogene; breast cancer; gene amplification; cyclophosphamide; breast neoplasms; monoclonal antibody; in situ hybridization; antibodies, monoclonal; fluorescence in situ hybridization; breast carcinoma; tamoxifen; receptor, erbb-2; taxane derivative; trastuzumab; anthracycline; hormone resistance; oncogene neu; her-2/neu; herceptin; humans; prognosis; human; female; priority journal; oncogene c erb; c-erb-b2 |
Journal Title: | Diagnostic Molecular Pathology |
Volume: | 10 |
Issue: | 3 |
ISSN: | 1052-9551 |
Publisher: | Lippincott Williams & Wilkins |
Date Published: | 2001-09-01 |
Start Page: | 139 |
End Page: | 152 |
Language: | English |
DOI: | 10.1097/00019606-200109000-00001 |
PUBMED: | 11552716 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Export Date: 21 May 2015 -- Source: Scopus |